We’re building the first universal virtual cell-signaling model to decode the language of cells—so biology is no longer destiny, but design.
- Tweets 142
- Following 23
- Followers 1,309
- Likes 96
Pinned Tweet
Today we’re sharing a defining moment for Cellular Intelligence.
We have entered into an agreement with @novonordisk to acquire STEM-PD, a Phase 2-ready allogeneic cell therapy program for Parkinson’s disease. Alongside the acquisition, Novo Nordisk is making a strategic investment in Cellular Intelligence.
This is one of the most advanced cell therapy programs in Parkinson’s. The program has an FDA-cleared IND for Phase 2 and Fast Track Designation, following completion of Phase 1/2 dosing in the underlying academic clinical program, STEM-PD.
This is more than an asset acquisition.
It marks the beginning of an AI-native era for cell replacement therapy.
One where biology is no longer destiny, but design.
Read all about it here: cellularintelligence.com/ste…
#CellTherapy #ParkinsonsDisease #Biotech #AIinBiotech #TechBio
STEM-PD is an investigational therapy; its safety and efficacy have not been established.
4
21
3,010
Congratulations to Cellular Intelligence Scientific Co-Founder Allon Klein @KleinLabHMS on being named a 2026 Schmidt Sciences @schmidtsciences Polymath.
Allon is Professor of Systems Biology at Harvard Medical School @harvardmed, working where physics, computation, and biology combine into one discipline. His research on how cells make decisions is foundational to what we're building at CI.
Congratulations as well to Allon’s fellow Polymaths, and to Schmidt Sciences for backing bold science that refuses to stay in one lane.
schmidtsciences.org/2026-pol…
6
4,566
Today we officially welcome Yann LeCun (@ylecun), Bob Langer, Jens Nielsen and Fabian Theis (@fabian_theis) to the Cellular Intelligence Scientific Advisory Board. Langer also joins our Board as an observer.
Four people who have changed what is possible in AI, biology and medicine, now working with us to learn the rules that govern how cells change, and carry that knowledge into medicine.
@FortuneMagazine's @CatGioino has the story: fortune.com/2026/09/21/moder…
4
14
72
5,442
We're excited to announce that Arjun Raj, Ph.D. @arjunrajlab has been appointed Chief Scientific Officer and named Scientific Co-Founder of Cellular Intelligence.
Arjun joined us full time in 2025 while on leave from @Penn, where he is the Richard K. Lubin Professor of Bioengineering and Professor of Genetics. A mathematician turned experimental systems biologist, he co-developed the method that made it possible to count individual RNA molecules inside single cells. In his first year here he architected our data engine and scientific program.
"What has always limited the field is the data," Arjun said. "For the first time, I can see a path from observing cellular decisions to predicting and eventually controlling them."
Congratulations Arjun!
🔗 Official announcement: prnewswire.com/news-releases…
1
8
100
74,010
Most medicines are molecules. STEM-PD is made of living cells.
Our new paper sets out why we acquired STEM-PD, our Phase 2-ready investigational cell therapy for Parkinson's disease, and how it connects to the foundation model of cell signaling we're building.
From Model to Medicine, and Back: cellularintelligence.com/fro…
1
7
2,921
Today we're welcoming two leaders to Cellular Intelligence who will help define its next chapter.
Jonathan Alspaugh joins as Chief Strategy Officer, bringing 15+ years across biopharma strategy, finance, and operations.
Adam Weinroth joins as Chief Marketing Officer, bringing two decades building and scaling AI and technology platforms.
Cellular Intelligence is working to understand the language cells use to communicate, and to turn that understanding into medicine. It's some of the most ambitious work happening in biology, and Jonathan and Adam arrive to help carry it forward.
🔗 Full Announcement: lnkd.in/ee63dY7u
Welcome to the team!
1
5
1,171
Today is a milestone for Parkinson's research, and it belongs to Lund.
A team led from Lund University has published the first-in-human clinical trial results for a stem-cell-derived cell therapy in Parkinson's disease, in Nature Medicine.
This is a landmark for regenerative medicine, built on four decades of dopamine-cell science pioneered at Lund, and a goal the field has worked toward for a generation.
Our congratulations to the entire STEM-PD team:
🔹 Malin Parmar, Project Lead, Lund University
🔹 Gesine Paul-Visse, Principal Investigator, Lund University and Skåne University Hospital
🔹 Roger Barker, Clinical Lead and Principal Investigator, University of Cambridge and Cambridge University Hospitals
🔹 Håkan Widner, Sponsor Representative and Co-Investigator, Lund University and Skåne University Hospital
🔹 Hjálmar Bjartmarz, Co-Investigator and Neurosurgeon, Skåne University Hospital
🔹 Agnete Kirkeby, Pre-clinical Development Lead, Lund University and University of Copenhagen
🔹 Paola Piccini, Brain Imaging, Imperial College London
🔹 Oskar Hansson, PET Imaging, Lund University
🔹 Ruben Smith, PET Imaging, Lund University and Skåne University Hospital
The trial was managed by the Cambridge Clinical Trials Unit Neuroscience theme and the Skåne University Hospital neurology research unit, with partners at University College London, and conducted in collaboration with Novo Nordisk.
Cellular Intelligence is proud to lead the next phase of STEM-PD's clinical development, including a planned Phase II trial. Today the moment belongs to Lund and the team who brought it here. Congratulations to all of them.
🔗 Read the study in Nature Medicine: nature.com/articles/s41591-0…
2
4
11
4,084
How is AI-bio moving from concept to clinical-stage impact?
Cellular Intelligence CEO @MichaBreakstone sat down with @CNBC 's @jonfortt to discuss how we're turning biology into a predictive engineering discipline.
Cell signaling is a language. Just as foundation models learned to predict ours, we're learning to predict theirs. When we get that right, we step into the era of programmable biology.
🎬 Watch the full conversation here: cnbc.com/video/2026/06/09/mi…
1
382
What is the future of AI x Bio?
Yesterday in Copenhagen, we set out to answer exactly that. At the @novonordiskfond headquarters, we convened leaders across AI, biology, regenerative medicine, venture, and company building for a day-long symposium on Engineering Cell Fate—and what we believe will become the next AlphaFold moment for biology. 🧵
3
2
9
844
Keynote & Speakers:
Mads Krogsgaard Thomsen, @nasdaily, @MatttBuckley, Thomas Carlsen, @StephanChr25527, @andreascleve, @johncumbers, @VitalayFomin, Gunner Laine Hardy, @kim_bak_jensen, Petrina Kamya, @Kirkeby_Lab, @MatLegut, @aijamayrock, @jb_michel, Jens Nielsen, @ParmarLab , Travis Potter, Tali Raveh, @ArmonSharei, @ReshefShilon, @NTallapragada, @aloktayi, @VallierLab, @PeterAksel
1
259
Founders & Leadership Team:
@MichaBreakstone, Olivier Pourquie, @JShendure, @arjunrajlab, @KleinLabHMS, Cliff Tabin, @TweetKJBrown, Tzvika Cohen, @SamanthaDStrass, Nuno Mendonça, Marianne Stemann Andersen.
1
143
This week at the @KeystoneSymp on Computational Advances in Drug Discovery, our VP of Strategy @SamanthaDStrass gave a spotlight talk, and @baagmery, Principal Scientist in Computational Biology, presented on the poster floor — joining the conversation at the frontier of computational drug discovery.
Their talk and poster showcased our multiplexed platform and its ability to generate data at unprecedented scale — the foundation for our work toward a Universal Virtual Cell-Signaling Model that predicts context-dependent signaling response and, ultimately, controls cell fate. This unlocks a range of applications: iPSC-based disease modeling, drug response prediction, target identification, and protocol design for cell therapies.
These capabilities turn biology from a trial-and-error science into predictive engineering.
Thank you to Keystone Symposia for the opportunity to share our work. We're building a future where biology is no longer destiny, but design.
#ksdrugdiscovery2026
@arjunrajlab, Kristy Brown, @KleinLabHMS, Olivier Pourquié
3
8
2,114
Today, our CEO @MichaBreakstone joined a brilliant panel alongside @iamjohnnyyu from @tahoe_ai and @glebkuz from @ManifoldBio—masterfully moderated by @FabioZB_I of Polyphron—to answer a pivotal question: Why now? 🧵
1
5
415
By capturing this scale, we can look at biology not as static states, but as dynamic transitions. We are moving away from empirical trial-and-error to essentially learning the grammar of cellular decision-making, which fundamentally transforms how we can engineer cell therapies and model disease.
1
166